Loading
companiesCompany
Adcendo
Adcendo is a Danish company developing antibody-drug conjugates, antibodies that deliver a cell-killing drug straight to cancer cells, against targets few others are pursuing. Its first medicines are in early human trials, including one for soft tissue sarcoma.
Overview
Adcendo ApS is a clinical-stage Copenhagen biotech developing antibody-drug conjugates against targets, such as tissue factor and uPARAP, that few other companies pursue. Its pipeline comprises ADCE-T02, a tissue factor-targeted ADC in the phase 1 Tiffany-01 study (cohort expansion in multiple solid tumour indications from April 2026, with a pembrolizumab combination cohort agreed with MSD in May 2026); ADCE-D01, a uPARAP-targeted ADC in the ADCElerate1 dose escalation and expansion study in soft tissue sarcoma and other mesenchymal cancers; and ADCE-B05, against an undisclosed target, in dose escalation in squamous cell carcinomas. The company closed an oversubscribed USD 135 million Series B in November 2024 led by TCGX, and a USD 75 million Series C in April 2026 led by Jeito Capital with Vida Ventures, Bpifrance and EIFO joining existing investors including RA Capital, Novo Holdings and Ysios Capital.
Headquarters
Copenhagen, DK
Funding
All startupsGrowth stage
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series C | 2026 | $75M | adcendo.com |
| Series B | 2024 | $135M | adcendo.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Growth stage
Website
Notes
top- Earlier Series A (2021) not fetched and omitted. Founding year not stated on fetched pages.
Similar pages
- CompanyAlentis Therapeutics
Shares Bpifrance, Jeito Capital, Novo Holdings, OrbiMed.
- CompanyObsidian Therapeutics
Shares TCGX (TCG Crossover), Logos Capital, Novo Holdings, RA Capital Management.
- CompanyCallio Therapeutics
Shares Jeito Capital, Novo Holdings, Antibody-drug conjugate (ADC).
- CompanyEnliven Therapeutics
Shares Venrock, RA Capital Management.
- CompanyNeogene Therapeutics
Shares Jeito Capital, Vida Ventures.
- CompanyAdela
Shares OrbiMed, RA Capital Management.
- CompanyTriana Biomedicines
Shares Logos Capital, RA Capital Management.
- CompanyMythic Therapeutics
Shares Venrock, Antibody-drug conjugate (ADC).